Delcath Systems Inc DCTH

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company's products, HEPZATO KIT (Hepzato (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan (CHEMOSAT) percutaneous hepatic perfusion (PHP) are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. HEPZATO KIT is a drug/device combination product designed to administer high-dose chemotherapy directly into the liver while limiting systemic exposure and associated side effects. In Europe, the hepatic delivery system is a stand-alone medical device having the same device components as HEPZATO KIT, but without the melphalan hydrochloride and is approved for sale under the trade name CHEMOSAT. In the United States, HEPZATO is regulated as a drug by the United States Food and Drug Administration (FDA).

NDAQ:DCTH - Post by User

Delcath Systems Inc > Very interesting, life extending system.

<< Previous

Bullboard Posts

Next >>

Post by ofnidon Jun 15, 2020 8:28pm

295 Views

Post# 31153677

Very interesting, life extending system.

Looking backwards this stock has been a disaster however their technology is being used in Europe to extend people's lives. Seems to have a very small market cap for what they have. Now that they have wiped out the former shareholders and recapitalized maybe it has a chance? Last financing was at $10.

<< Previous

Bullboard Posts

Next >>

FuelPositive installs first green ammonia system in Manitoba